Sermonix announces results from ELAINE-1 trial of Ligand’s Lasofoxifene

Sermonix Pharmaceuticals shared the results of an exploratory analysis evaluating the effects of patient characteristics on baseline vaginal/vulvar symptoms during its Phase 2 Evaluation of Lasofoxifene in ESR1 Mutations study. The findings were shared Sept. 28 in a poster presentation at The Menopause Society 2023 Annual Meeting. Assessing a limited number of patients with ER+/HER2- breast cancer, results showed that younger age, non-visceral disease, prior tamoxifen, and a longer total duration of aromatase inhibitor use in the adjuvant or metastatic settings may be associated with higher baseline vaginal and/or vulvar symptomatology. Patients had more severe vaginal/vulvar symptoms if they were under age 40 versus patients over 40, and if they did not have visceral disease compared with those who had visceral disease. Prior adjuvant tamoxifen was associated with more severe vaginal/vulvar symptoms, as was a longer total duration of AI use in both adjuvant and metastatic settings. Duration of prior AI in the adjuvant setting alone did not impact baseline vaginal or vulvar symptoms. Sermonix licensed Lasofoxifene globally from Ligand Pharmaceuticals